Figure 4. CR2-fH treatment effectively ameliorates GVHD and preserves the GVL effect.

Lethally irradiated B6 or BALB/c recipients were transplanted with WT B6 TCD-BM plus T-cells from luciferase-transduced B6 donors. On day 7 after HCT, labeled CR2-fH was injected via tail vein. (A) Experimental schematic (top) and representative BLI images (bottom) taken 9 days post-HCT are shown. (B) Representative images of labelled CR2-fH organ localization via Maestro system are shown. (C-E) Lethally irradiated B6 mice were transplanted with TCD-BM (5x10⁶/mouse) with or without T-cells (0.6x10⁶/mouse) from FVB donors and with or without luciferase-tranduced C1498 tumor cells. Recipient mice were treated with vehicle or CR2-fH every other day for 12 days. Survival (C) and clinical score (D) are shown. (E) Representative BLI images taken throughout the experiment are shown. The log-rank (Mantel-Cox) test (C), nonparametric Mann-Whitney U test (D) were used to compare between groups. Data is presented as mean ± S.E.M. and *p < 0.05, **p < 0.01, ***p < 0.001.